Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.00 – $0.13
0% from low
Exchange
OTC Link
CS
Borrow rate
0.25%
Easy to borrow
NASCENT BIOTECH INC
No one on the platform currently holds NBIO.
No tracked institution reports a position in NBIO as of their last filing.
No one on the platform has traded NBIO yet.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Fundamental analysis of $NBIO (Nascent Biotech Inc.) based on financial data and reported results. #NBIO #Nascent
View on StockTwits ↗$NBIO Still here. Still waiting. From what I know, some big whales holding millions of shares. They cannot be happy. So I wait with them hoping that something happens here./ok2
View on StockTwits ↗$NBIO Love to see a white knight here and a formal relisting on the OTC! Or even better, a buyout at a valuation that brings a smile for shareholders!
View on StockTwits ↗$NBIO Something happening again here today. Range of $0.0002-$0.0752 on over 800,000 shares traded. What does someone know here that the rest of us don't?? Anyone have any insight??
View on StockTwits ↗$NBIO If there is one lesson to be learned over the last couple days, this one can turn one way or the other very quickly. Still wishing the faithful longs the best of luck./
View on StockTwits ↗$NBIO Back to the shelf for this one. Oh well, I’ve long let go of the money I’ve lost here. It would’ve been nice to see Pritumumab get its chance to save lives, but it looks like it’s going nowhere.
View on StockTwits ↗$NBIO The joy is short-lived. 5,000 shares sold @ $0.0002/share./
View on StockTwits ↗$NBIO If PTB is backed by significant financial support or if it is sold to a large company that can fund Phase 2 & 3, then $1 is definitely possible. In 2023, Marble Arch Research specified a price range of $0.60-$2.84. https://www.nascentbiotech.com/marble-arch-research-what-is-pritumumab-and-how-it-works/
View on StockTwits ↗$NBIO From a new poster, asking if $1 is possible. From the company's info, the Glioblastoma market is expected to be $5.68 billion in the next 3-5 years. Lots of ifs, but if the drug can demonstrate efficacy, we have the right partner or the company outright sells, who knows?? Seems like a crazy number today, but do the math, without any dilution to shares, the share price would be unimagineable. But I'm getting ahead of myself. Best of luck to the longs./
View on StockTwits ↗$NBIO This study (Mar/2025), I believe validates pritumumab as a viable treatment for brain cancer. It looks to me like this is third party research. This could help give the company the necessary leverage to relist trading for all, (currently expert trading only designation?) and open up exciting new potential for partnerships or sale of the asset. These are my opinions only! Here is the link. Best of luck to the faithful longs./ok2 https://www.nature.com/articles/s41598-025-95360-9
View on StockTwits ↗$NBIO J1983 - Looking at the last 2 days of trading: Nov.10/25, $0.09, 40,000 shares sold, Nov.11/25, High $0.1345, Low $0.08, Close $0.084, 211,000 shares sold. Clearly someone is willing to buy shares and this demonstrates that there is value here. I remember reading somewhere that the company was looking for $0.25/share in unlocked potential. I guess we'll see. A call to my broker my shed some light on the trading status. Obviously someone can buy and sell./
View on StockTwits ↗$NBIO Thanks ok2buy - I hope so too. I know you’ve been in this longer than I have and I’ve been here 5 years. I’m hoping this amazing drug gets it shot!
View on StockTwits ↗$NBIO J1983 - I posted a few days back that I thought something was up. Someone was accumulating shares on the cheap. I tried to buy, I can place an order, but my trading platform ultimately rejects the order. Perhaps, either 1) management has secured new funding or 2) there is a sale of the company or it's assets. Either way, I am hoping that this is good news for existing shareholders. I am going to try to see if we are back in compliance and can be traded again. Best of luck to the faithful longs./
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.